tiprankstipranks
Trending News
More News >
Coherus Biosciences (CHRS)
NASDAQ:CHRS

Coherus Biosciences (CHRS) Stock Statistics & Valuation Metrics

Compare
1,593 Followers

Total Valuation

Coherus Biosciences has a market cap or net worth of $86.15M. The enterprise value is $1.02B.
Market Cap$86.15M
Enterprise Value$1.02B

Share Statistics

Coherus Biosciences has 115,933,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding115,933,270
Owned by Insiders1.13%
Owned by Institutions18.62%

Financial Efficiency

Coherus Biosciences’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -66.77%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)-66.77%
Return on Capital Employed (ROCE)-0.67
Revenue Per Employee1.17M
Profits Per Employee125.03K
Employee Count228
Asset Turnover0.60
Inventory Turnover1.68

Valuation Ratios

The current PE Ratio of Coherus Biosciences is 5.55. Coherus Biosciences’s PEG ratio is -0.51.
PE Ratio5.55
PS Ratio0.00
PB Ratio-4.47
Price to Fair Value-1.20
Price to FCF-2.53
Price to Operating Cash Flow-2.55
PEG Ratio-0.51

Income Statement

In the last 12 months, Coherus Biosciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.
Revenue266.96M
Gross Profit149.41M
Operating Income-111.67M
Pretax Income28.51M
Net Income28.51M
EBITDA60.94M
Earnings Per Share (EPS)0.25

Cash Flow

In the last 12 months, operating cash flow was 500.00K and capital expenditures 0.00, giving a free cash flow of 500.00K billion.
Operating Cash Flow500.00K
Free Cash Flow500.00K
Free Cash Flow per Share<0.01

Dividends & Yields

Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.44
52-Week Price Change-45.32%
50-Day Moving Average0.86
200-Day Moving Average1.05
Relative Strength Index (RSI)46.28
Average Volume (3m)1.19M

Important Dates

Coherus Biosciences upcoming earnings date is Jul 31, 2025, After Close (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date

Financial Position

Coherus Biosciences as a current ratio of 1.21, with Debt / Equity ratio of -342.79%
Current Ratio1.21
Quick Ratio0.96
Debt to Market Cap1.68
Net Debt to EBITDA2.36
Interest Coverage Ratio-4.11

Taxes

In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Coherus Biosciences EV to EBITDA ratio is 4.96, with an EV/FCF ratio of -14.77.
EV to Sales1.13
EV to EBITDA4.96
EV to Free Cash Flow-14.77
EV to Operating Cash Flow-14.77

Balance Sheet

Coherus Biosciences has $82.41M in cash and marketable securities with $231.42M in debt, giving a net cash position of $149.01M billion.
Cash & Marketable Securities$82.41M
Total Debt$231.42M
Net Cash$149.01M
Net Cash Per Share$1.29
Tangible Book Value Per Share-$1.62

Margins

Gross margin is 66.79%, with operating margin of -41.83%, and net profit margin of 10.68%.
Gross Margin66.79%
Operating Margin-41.83%
Pretax Margin10.68%
Net Profit Margin10.68%
EBITDA Margin22.83%
EBIT Margin20.85%

Analyst Forecast

The average price target for Coherus Biosciences is $4.03, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.03
Price Target Upside430.26% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast-34.58%
EPS Growth Forecast-62.19%

Scores

Smart Score5
AI Score45
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis